Biotech Calendar: Key Dates for November
BOSTON, Mass. (TheStreet) -- A calendar of important, potentially stock-moving biotech events for November:
Nov. 2
Dendreon (DNDN) third-quarter earnings. Will Provenge sales recover?
Nov. 3-5
North American Cystic Fibrosis Conference: Vertex Pharmaceuticals (VRTX) presenting Kalydeco data.
Nov. 4-8
American Association for the Study of Liver Disease (AASLD) annual meeting. Key presentations of hepatitis C drug data from Pharmasset (VRUS), Bristol-Myers Squibb (BMY), Vertex Pharmaceuticals, Merck (MRK), Johnson & Johnson (JNJ) and others.
American College of Rheumatology (ACR) annual meeting. Nov. 7
Roche (RHHBY) analyst/investor meeting.
American Society of Hematology (ASH) annual meeting research abstracts released: Ariad Pharmaceuticals (ARIA), Celgene (CELG), YM BioSciences (YMI). Nov. 10
Merck analyst/investor meeting. Nov. 11
FDA approval decision for Alimera Sciences (ALIM) and pSivida's (PSDV) Iluvien for diabetic macular edema. Nov. 12-16
American Heart Association Scientific Sessions: Aastrom Biosciences (ASTM), Amarin (AMRN).
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Nov. 13
FDA approval decision for IntelGenx's (IGXT.OB) CPI-300 anti-depressant. Nov. 16
FDA advisory panel convened to review Salix Pharmaceuticals' (SLXP) Xifaxan for irritable bowel syndrome with diarrhea. Nov. 18
FDA approval decision for Regeneron Pharmaceuticals' (REGN) Eyelea for age-related macular degeneration. Nov. 27
FDA approval decision for Transcept Pharmaceuticals' (TSPT) Intermezzo sleeping pill. --Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: tips@thestreet.com. Follow TheStreet on Twitter and become a fan on Facebook.
Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
